News
-
Roche's Trastuzumab Emtansine (T-DM1) Showed Positive Phase III Results In HER2-Positive Metastatic Breast Cancer
4/2/2012
Roche recently announced topline results of EMILIA, the first randomised Phase III study of trastuzumab emtansine (T-DM1).
-
Ampio Announces Positive Preliminary Update On The Optina™ Clinical Trial To Treat Diabetic Macular Edema And Decision To Conclude The Study Ahead Of Schedule
3/20/2012
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Zertane™ completed two phase III studies, Ampion™-completed proof of concept studies and Optina™), licensing distribution of these drugs and engaged in further drug development, today announced that it completed the planned interim review of the first 50% of patients enrolled in the Optina™ trial for diabetic macular edema.
-
Roche´s MagNA Pure LC 2.0 System For Monitoring DNA In Therapeutic Proteins And Monoclonal Antibody Drugs
3/2/2012
To ensure product safety, clearance of host-cell DNA is essential when manufacturing therapeutic proteins and monoclonal antibody (mAB) drugs.
-
Jubilant And Endo Pharmaceuticals Announce Successful Delivery Of Early Milestones In Collaborative Discovery Program
2/14/2012
Jubilant Biosys Ltd., a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today that they have achieved an early stage milestone in one of their collaborative programs with Chadds Ford, Pa., USA-based Endo Pharmaceuticals that has nominated a candidate into full development.
-
Roche's xCELLigence Cardio Instrument Used To Detect Beating Rhythm And Proarrhythmic Effects Of Compounds In Stem Cell-Derived Cardiomyocytes
2/10/2012
In an effort to improve preclinical cardiotoxicity assays, reduce drug testing attrition rates, and ensure drug safety, collaborating scientists at the University Medical Center Utrecht in the Netherlands, and Bioscience Department of AstraZeneca R&D, Mölndal, Sweden, have tested Roche’s xCELLigence Cardio Instrument.
-
Lubiprostone Meets Primary Endpoint In Phase 3 Clinical Trial For Opioid-Induced Bowel Dysfunction (OBD)
2/3/2012
Sucampo Pharmaceuticals, Inc. (SPI) and Takeda Pharmaceuticals U.S.A., Inc. announced recently that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
-
Ampio Pharmaceuticals, Inc. Announces Statistically Significant Improvement In Pain Relief For Its Lead Product, Ampion In The Osteoarthritis Of The Knee Trial
2/1/2012
Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced preliminary results of the pain score portion of the expansion phase of Ampion™ in Knee (AIK) trial which was recently completed in Australia.
-
BrainStorm Announces Clinical Data For Safety And Supporting Efficacy Of NurOwn™ Based On Initial Phase I/II Results
1/18/2012
BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI), an innovative developer of adult stem cell technologies and Central Nervous System (CNS) therapeutics, recently announced that the data from the initial patients in its ALS Phase I/II human clinical trial treated with its NurOwn™ technology did not present any significant side effects and that the NurOwn™ treatment has so far proven to be safe.
-
Roche´s GS Junior Sequencing System Used In Research On Personalized Tumor Treatment
1/18/2012
The Center for Human Genetics and Laboratory Medicine Dr. Klein and Dr. Rost, and IMGM Laboratories, both located in Martinsried Germany, reported using the Roche GS Junior Benchtop System to sequence clinically relevant exons and identify genomic variations in solid tumors treated with an antibody-based medicine.
-
Neuralstem's NSI-189 Trial In Major Depressive Disorder Receives FDA Approval To Advance To Phase Ib
12/27/2011
Neuralstem, Inc. (NYSE Amex: CUR) announced that it has been approved by the Food and Drug Administration to advance to Phase Ib in its ongoing clinical trial to test its novel neuroregenerative compound, NSI-189, for the treatment of major depressive disorder (MDD).
This website uses cookies to ensure you get the best experience on our website. Learn more